Grifols (GIKLY) Non-Current Deferred Tax Liability (2009 - 2025)

Grifols (GIKLY) posted Non-Current Deferred Tax Liability of $1.0 billion for Q4 2025, down 7.32% quarter-over-quarter from $1.1 billion in Q4 2024, and down 7.32% year-on-year from $1.1 billion in Q4 2024.

Grifols (GIKLY) Non-Current Deferred Tax Liability (2009 - 2025) Analysis & Trends

Grifols (GIKLY) has reported Non-Current Deferred Tax Liability for 16 consecutive years, with $1.0 billion the latest figure, recorded in Q4 2025.

  • Non-Current Deferred Tax Liability for Q4 2025 came in at $1.0 billion, down 7.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 billion (down 7.32% YoY), and the FY2025 annual result was $1.0 billion, down 7.32% from the prior year.
  • Non-Current Deferred Tax Liability was $1.0 billion for Q4 2025 at Grifols, down from $1.1 billion in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $1.1 billion in Q4 2024 and troughed at $725.3 million in Q4 2021.
  • Average Non-Current Deferred Tax Liability over 5 years is $985.7 million, with a median of $1.1 billion recorded in 2022.
  • Year-over-year, Non-Current Deferred Tax Liability surged 45.57% in 2022 and dropped 7.32% in 2025.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $725.3 million in 2021, then surged by 45.57% to $1.1 billion in 2022, then grew by 0.75% to $1.1 billion in 2023, then increased by 1.67% to $1.1 billion in 2024, then decreased by 7.32% to $1.0 billion in 2025.
  • Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $1.0 billion in Q4 2025, $1.1 billion in Q4 2024, and $1.1 billion in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Grifols - - -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.00 Bn
Dec 31, 2025 1.00 Bn
Dec 31, 2024 1.08 Bn
Dec 31, 2024 1.08 Bn
Dec 31, 2023 1.06 Bn
Dec 31, 2023 1.06 Bn
Dec 31, 2022 1.06 Bn
Dec 31, 2022 1.06 Bn
Dec 31, 2021 725.26 Mn
Dec 31, 2021 725.26 Mn
Dec 31, 2020 663.88 Mn
Dec 31, 2020 663.88 Mn
Dec 31, 2019 377.23 Mn
Dec 31, 2019 377.23 Mn
Dec 31, 2018 333.13 Mn
Dec 31, 2018 333.13 Mn
Jun 30, 2018 470.02 Mn
Jun 30, 2018 470.02 Mn
Dec 31, 2017 457.92 Mn
Dec 31, 2017 457.92 Mn